CLIMB BIO, INC. Foreign Currency Transaction Gain (Loss), Unrealized
CLIMB BIO, INC. (CLYM) reported Foreign Currency Transaction Gain (Loss), Unrealized of -$5.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-08-06
- CLIMB BIO, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-06-30 was $16.00K.
- CLIMB BIO, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2026-03-31 was -$21.00K.
- CLIMB BIO, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-12-31 was $5.00K.
- CLIMB BIO, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was $1.00K, a 99.07% decline year-over-year.
- CLIMB BIO, INC. foreign currency transaction gain (loss), unrealized for fiscal 2025 was -$18.00K, a 142.86% decline from fiscal 2024.
- CLIMB BIO, INC. foreign currency transaction gain (loss), unrealized for fiscal 2024 was $42.00K.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 3 month | Foreign Currency Transaction Gain (Loss), Unrealized 6 month | Foreign Currency Transaction Gain (Loss), Unrealized 9 month | Foreign Currency Transaction Gain (Loss), Unrealized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$5.00K 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $1.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$21.00K 10-Q · filed 2026-05-07 | -$16.00K derived: sum of 2 quarters · filed 2026-05-07 | -$15.00K derived: sum of 3 quarters · filed 2026-05-07 | -$15.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $6.00K derived: sum of 2 quarters · filed 2026-03-05 | $6.00K derived: sum of 3 quarters · filed 2026-08-06 | -$18.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.00K derived: sum of 2 quarters · filed 2026-08-06 | -$23.00K 10-Q · filed 2025-11-06 | -$80.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$24.00K 10-Q · filed 2026-08-06 | -$81.00K derived: sum of 3 quarters · filed 2026-08-06 | $27.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$24.00K 10-Q · filed 2026-05-07 | -$81.00K derived: sum of 2 quarters · filed 2026-05-07 | $27.00K derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $51.00K derived: sum of 2 quarters · filed 2026-03-05 | $42.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $99.00K 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$9.00K 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |